🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchClinicalTrials.gov GLP-1 trial tracker — updated weekly Page 18

ClinicalTrials.gov GLP-1 trial tracker — updated weekly

TrialTracker_MD Mon, Feb 26, 2024 at 4:00 PM 411 replies 11,865 viewsPage 18 of 20
MASHdoc_SA
Member
456
2,345
Aug 2024
San Antonio, TX
Sep 10, 2025 at 4:08 AM#86
PeptideChemSF said:
If you are going to change something, change one thing and give it long enough to express itself.

Bookmarking. The distinction being drawn above is the one nobody else makes.

Last edited: Sep 10, 2025 at 7:08 AM
19 17TirzTom, TrialTracker_MD, JennaRN and 16 others
Reply Quote Save Share Report
rachel_ABQ
Member
178
890
Dec 2024
Albuquerque, NM
Sep 18, 2025 at 3:27 AM#87

Adding the clinical framing, because it changes how the question reads. The version of this that has an answer is narrower than the version being asked. Narrow it and it becomes tractable; leave it broad and the thread will produce nine confident and incompatible replies.

20 18DadBodDave, AmyNC_wife, SkepticalSean and 17 others
Reply Quote Save Share Report
RunnerRach
Member
467
2,123
Aug 2024
Boston, MA
Sep 26, 2025 at 2:42 AM#88

Found this through search years later and it is still the best discussion of the question, so adding one thing. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.

21 19Dr.RaviCardio, jennifer_SEA, tyler_CSCS and 18 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Admin
Administrator
2,456
9,812
Oct 2023
Online
Oct 4, 2025 at 1:52 AM#89

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Report rather than reply if it drifts again.

22 20BiostatsBrad, PeptideSynthNJ, Dr.KarenChen and 19 others
Reply Quote Save Share Report
Dr.PeteFamMed
Senior Member
2,012
9,234
Jan 2024
Minneapolis, MN
Oct 12, 2025 at 12:58 AM#90

One concrete data point for the thread. One habit that pays for itself: post the method alongside the number. A figure without its method cannot be checked, and an unchecked figure is how this community accumulates folklore.

Last edited: Oct 12, 2025 at 1:58 AM
44 17FranDenver, Dr.BariatricHTX, LindaRN_retired and 41 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register